COHANCE
Cohance Lifesciences Limited (COHANCE) Stock Analysis
Cohance Lifesciences Limited is an Indian contract development and manufacturing organisation for pharma. It produces APIs and intermediates for innovator and generic companies worldwide. Capacity utilisation and regulatory approvals underpin export revenues from India. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹445.60
-2.16% 1W | -48.90% 52W
Market Cap
17.0k CR
P/E Ratio
163.2
52W High
₹917.9
52W Low
₹266.7
Div. Yield
0%
Beta
0.6
50 DMA
₹448.6
200 DMA
₹405.8
Profit Margin
5%
Inst. Own.
23%
📉 CONSOLIDATING DOWN
📉 CONSOLIDATING DOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 348 | 231 | 220 | 253 | 488 | 604 | 676 | 840 | 549 | 556 | 545 | 619 | 422 |
| Expenses | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 |
| Operating Profit | 167 | 98 | 66 | 73 | 125 | 205 | 237 | 229 | 112 | 121 | 95 | 99 | 1 |
| OPM % | 48% | 42% | 30% | 29% | 26% | 34% | 35% | 27% | 20% | 22% | 18% | 16% | 0.3% |
| Other Income | 11 | 20 | 14 | 17 | 19 | 16 | 22 | -4 | 6 | 16 | 1 | -18 | 12 |
| Interest | 1 | 0 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 |
| Depreciation | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 |
| Profit before tax | 164 | 105 | 65 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 |
| Tax % | 26% | 25% | 29% | 25% | 27% | 21% | 25% | 27% | 26% | 21% | 29% | 58% | 5% |
| Net Profit | 121 | 80 | 47 | 53 | 75 | 138 | 153 | 117 | 46 | 66 | 29 | 8 | -45 |
| EPS in Rs | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 |
| Metric | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|
| Sales | 378 | 834 | 1,010 | 1,320 | 1,340 | 1,051 | 2,608 | 2,269 | 2,142 |
| Expenses | 206 | 449 | 567 | 738 | 766 | 645 | 1,811 | 1,841 | 1,825 |
| Operating Profit | 172 | 385 | 443 | 582 | 574 | 406 | 797 | 427 | 316 |
| OPM % | 45% | 46% | 44% | 44% | 43% | 39% | 31% | 19% | 15% |
| Other Income | 1 | 66 | 68 | 133 | 46 | 62 | 53 | 4 | 11 |
| Interest | 3 | 23 | 12 | 9 | 13 | 7 | 41 | 37 | 34 |
| Depreciation | 12 | 24 | 32 | 39 | 48 | 55 | 167 | 187 | 192 |
| Profit before tax | 158 | 405 | 468 | 668 | 560 | 406 | 643 | 207 | 101 |
| Tax % | 31% | 22% | 23% | 32% | 27% | 26% | 25% | 27% | |
| Net Profit | 109 | 317 | 362 | 454 | 411 | 300 | 484 | 150 | 59 |
| EPS in Rs | 12.45 | 14.23 | 17.83 | 16.16 | 11.80 | 19.14 | 4.68 | 2.78 | |
| Dividend Payout % | -0% | 20% | 14% | 28% | 37% | -0% | -0% | -0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 19.0% | 18.0% | – |
| Profit CAGR | -23.0% | -12.0% | – |
Shareholding Pattern
Promoters66.41%
FIIs7.23%
DIIs11.40%
Public14.95%
Promoters57.49%
FIIs6.51%
DIIs20.81%
Public15.16%
Promoters57.49%
FIIs6.01%
DIIs21.57%
Public14.91%
Promoters57.49%
FIIs5.59%
DIIs21.79%
Public15.11%
Promoters57.49%
FIIs6.50%
DIIs20.09%
Public15.92%
Promoters60.00%
FIIs9.47%
DIIs11.43%
Public19.10%
Promoters50.10%
FIIs9.54%
DIIs17.24%
Public23.11%
Promoters50.10%
FIIs11.05%
DIIs16.60%
Public22.24%
Promoters57.49%
FIIs5.59%
DIIs21.79%
Public15.11%
Promoters57.49%
FIIs6.50%
DIIs20.09%
Public15.92%
COHANCE
Holdings Analysis
Key strengths & risk signals
58
Overall
50
Fundamental
67
Technical
Risks (4)
Cannot calculate PEG - insufficient growth data.
POOR YEAR! Stock declined 48.9% in the last year.
RECOVERY MODE! Current price (445.6) above 200-day but below 50-day.
LOWER HALF! Trading at 27.5% of 52W range - weakness visible.
Strengths (3)
BULLISH TREND! 50-day average (448.6) is above 200-day average (405.8) - positive signal.
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 1,511,205 vs down days: 710,346. Ratio: 2.13x
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
Fundamental & Technical Analysis
58Overall
50Fundamental
67Technical
Fundamental Breakdown
Growth Quality
15/30
Revenue CAGR: 18.3% (VERY GOOD, 13/15). Profit CAGR: -24.2% (DECLINING, 2/15).
Profit Margin
3/10
LOW MARGIN! 5.0% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
16/20
LESS PUBLIC HOLDING! 19.88% public ownership - good institutional/promoter control.
Stability Index
2/10
CAUTION! Company made loss in last quarter. Be careful.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (448.6) is above 200-day average (405.8) - positive signal.
Price Position
2/10
RECOVERY MODE! Current price (445.6) above 200-day but below 50-day.
Trend Pattern
10/20
Current trend: CONSOLIDATING DOWN
52W Performance
0/10
POOR YEAR! Stock declined 48.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 14 up days, 16 down days. Avg volume on up days: 1,511,205 vs down days: 710,346. Ratio: 2.13x
RSI
3/5
NEUTRAL! RSI at 49.0 - balanced momentum.
52W Range
2/5
LOWER HALF! Trading at 27.5% of 52W range - weakness visible.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -2.2% (1 week), 1.2% (1 month), 0.9% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.60 - stable stock, less market risk.
COHANCE
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-11 | Concall PDF | |
| Q4FY262026-05-15 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COHANCE | ₹445.60 | 163.2 | 5.0% | 18.3% | -24.2% | -48.9% | 58 | CONSOLIDATING DOWN | -149.3% | -223.0% | -23.1% | -31.8% |
| ALIVUS | ₹1,348.00 | 27.5 | 23.3% | 6.9% | 6.5% | +44.0% | 70 | APPROACHING RESISTANCE | +31.8% | -1.6% | +6.4% | -7.1% |
| CAPLIPOINT | ₹2,338.20 | 26.8 | 29.1% | 14.3% | 19.4% | +19.8% | 76 | BREAKDOWN | +15.8% | +4.0% | +19.6% | +1.7% |
| ERIS | ₹1,149.60 | 24.5 | 20.0% | 23.3% | 17.5% | -27.0% | 64 | BREAKDOWN | +20.7% | -49.4% | +12.6% | +15.5% |
| APLLTD | ₹792.50 | 22.7 | 8.9% | 9.5% | 25.4% | -14.0% | 74 | CONSOLIDATING UP | +12.1% | -14.6% | +25.7% | +16.4% |
| SHILPAMED | ₹962.10 | 67.9 | 17.7% | 13.8% | – | +173.0% | 66 | BREAKDOWN | +115.1% | -6.4% | +44.9% | +6.6% |
| JUBLPHARMA | ₹938.90 | 42.4 | 4.1% | 9.8% | – | -12.4% | 54 | BREAKDOWN | -45.1% | -52.7% | +18.2% | -2.2% |
| ASTRAZEN | ₹5,950.50 | 87.7 | 7.0% | 31.3% | 23.6% | -35.3% | 56 | APPROACHING SUPPORT | -32.1% | -15.6% | +29.7% | +18.0% |
Data from TradeAlone · Updated daily
COHANCE News
Cohance Lifesciences Limited (cohance) Announces USD 18 Million Investment to Strengthen ADC Strategy2026-09-03Cohance Lifesciences Limited (NSE: COHANCE) breaks out, moves up 5% intraday2026-08-11Cohance Lifesciences Limited (cohance) Announces Q1fy27 Results: Q1 as Guided, Strong Growth Rebound in H22026-08-05Cohance Lifesciences Limited (COHANCE) shows pressure after breakout, falls 5% intraday2026-07-08Cohance Lifesciences Limited (NSE: COHANCE) breaks out, gains 12% intraday2026-06-23Cohance Lifesciences Limited (NSE: COHANCE) climbs up 5% intraday2026-06-23Cohance Lifesciences Limited (cohance) FY26 Q4 Results: Strategic Growth Alignment for FY272026-05-12
